Justin Chakma - 12 Dec 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Chief Business Officer
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Issuer symbol
SPRY
Transactions as of
12 Dec 2024
Net transactions value
-$1,630,262
Form type
4
Filing time
13 Dec 2024, 19:53:20 UTC
Previous filing
12 Dec 2024
Next filing
03 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $98,560 +117,333 +86% $0.8400 253,713 12 Dec 2024 Direct
transaction SPRY Common Stock Sale $1,439,124 -117,333 -46% $12.27 136,380 12 Dec 2024 Direct F1
transaction SPRY Common Stock Options Exercise $39,272 +27,272 +20% $1.44 163,652 13 Dec 2024 Direct
transaction SPRY Common Stock Sale $328,968 -27,272 -17% $12.06 136,380 13 Dec 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -117,333 -50% $0.000000 119,047 12 Dec 2024 Common Stock 117,333 $0.8400 Direct F3
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -27,272 -33% $0.000000 55,461 13 Dec 2024 Common Stock 27,272 $1.44 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average sale price for the transaction reported was $12.2653, and the range of prices were between $11.83 and $12.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F2 The weighted average sale price for the transaction reported was $12.0625, and the range of prices were between $11.83 and $12.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3 Immediately exercisable.